Research window: 23–30 October 2026. Published 5 November 2026 as a late edition; the title identifies the research week.
Two trials illustrate why formulation and uncertainty matter: a modest cholesterol change with an enriched food, and an inconclusive neonatal omega-3 result with a safety signal. This is a focused roundup, not a systematic review.
1. Enriched soymilk: a modest extra LDL reduction
Read the trial — European Journal of Nutrition, 25 October 2026. DOI: 10.1007/s00394-026-04138-w.
In 242 adults with elevated LDL cholesterol, eight weeks of soymilk containing added plant sterols and inulin produced an adjusted LDL reduction 5.5 mg/dL greater than plain soymilk (95% CI 0.6–10.4). The daily enriched-food intake supplied 2 g plant sterols and 10 g added inulin; both groups received soy protein.
Interpretation: the additional effect was modest and cannot be attributed to plant sterols alone. This was a cholesterol-marker study, not a test of heart attacks or lifespan. The trial took place in 2013–2014 and was retrospectively registered. Exploratory subgroup findings should not drive treatment decisions.
Practical takeaway: this result concerns a specific combined food formulation. It does not justify replacing prescribed lipid treatment or assuming the same effect from any sterol capsule. See the previous update for a different plant-sterol trial; different results require comparison of populations and interventions, not a vote count.
2. Neonatal DHA: uncertain benefit, safety signal
Read the trial — BMC Pediatrics, 29 October 2026. DOI: 10.1186/s12887-026-07968-z. The publisher identifies this as a peer-reviewed accepted version awaiting further editing.
A single-centre, open-label trial allocated 62 preterm infants to a three-day enteral omega-3 course or standard care. Definite necrotising enterocolitis occurred in 7/29 versus 15/33 infants (risk ratio 0.53; 95% CI 0.25–1.12). The interval includes no benefit, so the apparently large numerical difference is not a reliable demonstration of prevention.
Mild neutropenia occurred in six supplemented infants and none receiving standard care. The authors reported no funding or competing interests.
Practical takeaway: an uncertain primary result and a blood-cell safety signal call for further investigation. This specialist neonatal intervention provides no basis for parents to supplement preterm infants themselves and cannot be extrapolated to routine adult fish-oil use.
Educational research summary, not individual treatment advice. Source pages checked 5 November 2026. Findings apply to the populations and formulations studied. How we assess evidence · Medical Disclaimer